Moving toward Personalized Medicine in the Methadone Maintenance Treatment Program: A Pilot Study on the Evaluation of Treatment Responses in Taiwan
Table 2
Frequencies of CYP2B6, CYP2C19, and ABCB1 polymorphisms in responders and nonresponders to treatment ()a.
Genotype
Responders ()
Nonresponders ()
value
CYP2B6
A785G (*4)
A/A
29 (47.5)
72 (62.6)
0.15
A/G
26 (42.6)
35 (30.4)
G/G
6 (9.9)
8 (7.0)
G516T (*9)
G/G
38 (62.3)
86 (74.8)
0.10
G/T
19 (31.1)
27 (23.5)
T/T
4 (6.6)
2 (1.7)
CYP2C19
G651A (*2)
G/G
27 (44.3)
63 (54.8)
0.21
G/A
32 (52.5)
45 (39.1)
A/A
2 (3.2)
7 (6.1)
G636A (*3)
G/G
53 (86.9)
105 (91.3)
0.14
G/A
6 (9.8)
10 (8.7)
A/A
2 (3.3)
0 (0)
C3402T (*17)
C/C
60 (98.4)
114 (99.1)
0.64
C/T
1 (1.6)
1 (0.9)
T/T
0 (0)
0 (0)
ABCB1 Genotype
C1236T
C/C
5 (8.2)
15 (13.0)
0.53
C/T
30 (49.2)
49 (42.6)
T/T
26 (42.6)
51 (44.4)
G2677T
G/G
22 (36.1)
26 (22.6)
0.03*
G/T
21 (34.4)
63 (54.8)
T/T
18 (29.5)
26 (22.6)
C3435T
C/C
30 (49.2)
39 (33.9)
0.02*
C/T
20 (32.8)
63 (54.8)
T/T
11 (18.0)
13 (11.3)
aNo available data on genotype for two subjects (1 responder and 1 nonresponder) due to methodological problems.
*Statistical significance set at ; comparisons were performed by the Chi-square test or Fisher’s exact test as appropriate.
